1 The pharmacokinetic and pharmacodynamic properties of the angiotensin converting enzyme (ACE) inhibitor cilazapril were studied in 30 hypertensive patients with various degrees of renal function. 2 After a single oral dose, apparent cilazaprilat clearance was dependent on renal function being 16.0 + 3.0, 11.1 + 3.0, 8.7 +3.7 and 6.7 + l l l h "1 (means+ s.d.) in patients with creatinine clearances (CLcr) of >100, 41-100, 21-40, and 8-20 ml min" 1, respectively. 3 During 11 weeks of treatment with cilazapril, doses were adjusted to the CLcr and varied from 0.5 to 5.0 mg once daily. At 24 h after drug administration a clear antihypertensive response was seen only in the low clearance groups (CLcr< 4 0 m l min-1 ) . In contrast, and despite higher once daily dosages, the decline of mean arterial pressure was small and cilazaprilat concentrations after 24 h were lower in the high clearance groups. 4 This study demonstrates that chronic once daily treatment with cilazapril is effective in patients with impaired renal function at dosages adjusted to creatinine clearance. No accumulation was seen. Since cilazaprilat clearance was high in the high creatinine clearance groups, a clear antihypertensive response in these groups was only seen at 3 h after drug administration.
The ACE inhibitor cilazapril is hydrolysed predomi nantly in the liver and blood to its active form cilazaprilat. This metabolite is excreted mainly by the kidneys [1] . In patients with normal renal function most of the unbound cilazaprilat is rapidly excreted in the first 8 h after drug administration. However, probably due to the high affinity of cilazaprilat for angiotensin converting enzyme the terminal half-life of this drug is as long as 40 to 50 h [1, 2] . In patients with renal insufficiency only limited pharmacokinetic and pharmacodynamic data on chronic cilazaprilat administration are available [3] [4] [5] . Therefore, we investigated the pharmacokinetic properties of cilazapri lat in hypertensive patients with various degrees of renal insufficiency both after a single dose as well as during chronic treatment. The antihypertensive and antiproteinuric effects of various dosages of cilazapril as well as their relation to creatinine clearance (CLor) and angiotensin converting enzyme (ACE) inhibition were studied at different times after drug administration.
Methods
Thirty hypertensive patients without other serious cardiovascular disorders and with various but stable levels of renal function were selected. At least 3 weeks before the start of the study all antihypertensive agents and any other drug possibly interfering with blood pressure regulation or renal function were discontinued. and ACE activity were performed by radioenzymatic Patients were divided in four groups: creatinine clearance methods [1] . During chronic treatment these were (CLcr)> 100 ml m in" 1 (group A), CLcr 41-100 ml min" 1 (group C) and CL (group B), CLcr 21-40 ml min 1 measured at all visits at 24 h after drug administration r and additionally at week 2 and 4 at 3 h after drug 8-20 ml min ~1 (group D). After three baseline measure-administration. At each visit serum potassium and ments of haemodynamic and laboratory parameters on creatinine were measured. Other routine blood evaluseparate days performed at the same time in the morning, ations remained stable throughout the study. At baseline patients received a single (either 0.5 or 1.0 mg) oral dose plasma renin activity (PRA) was determined by radioof cilazapril. During the subsequent 4 days, haemo-immunoassay [6] . In 24 h urine samples, concentrations dynamic and laboratory parameters were assessed at of creatinine, sodium, potassium, and protein were regular intervals. Thereafter, patients were treated during measured at baseline and during chronic treatment. 11 weeks with a single daily dose of cilazapril (see below).
Patients were ad vised to adhere to a constant intake of Control visits were performed at weekly intervals during sodium (150 mmol day" 1) and potassium (60-70 mmol the first 4 weeks and further at week 7 and 11. day 1 ) which was confirmed by urinary excretion. The study protocol was approved by the Ethical Committee of the University Hospital in Nijmegen. All patients gave their written informed consent.
For analysis, only relative changes of mean arterial
Blood pressure measurements pressure (MAP) compared with baseline were used. In one patient of group D the study was discontinued at At baseline standard sphygmomanometer supine dias-week 3 because of peritonitis. In this patient only results tolic blood pressure (BP) was greater than 90mmHg.
of the single dose part were used for analysis. For All other BP and heart rate (HR) measurements were determination of cilazaprilat pharmacokinetics individdone by automatic devices (DINAMAP, Criticon Inc., ual data were analyzed by non-compartmental methods Tampa, Florida or BOSCH EBM502, Bosch GMBH, [7 ] . Cilazaprilat peak concentrations (Cmax) and time Berlin, Germany). After 5 min supine rest, BP was to peak (imax) were directly observed from analytical measured at 1 min intervals for 3 min in supine position results. Since the decline of the logarithm of cilazaprilat using the same arm throughout the study. During concentrations is essentially non-linear and may vary chronic treatment, BP and HR were always measured widely [2, 8] , calculation of the area under the curve
24 h after drug administration at the same time in the morning, with additional measurements 3 h after drug to infinity may be unreliable. Therefore, the after the first dose was also calculated by the administration at weeks 2 and 4. The dose of cilazapril trapezoidal method to 24 h (AUC(0, 24 h)). Since was increased after 2 weeks of treatment (see below) if dosages of cilazapril were different in the high (AB) and diastolic blood pressure reduction 24 h after drug low clearance groups (CD), AUC (0, 24 h) and C administration was less than 10% or if diastolic blood were normalized to a dose of 1 mg for comparison of pressure remained higher than 90 mml-Ig. Thus the the results in the respective clearance groups. Apparent max cilazapril dose was increased in seven, five, four and four patients of group A, B, C, and D, ref Since patient numbers were small, data were analyzed oral clearance (CL0) was calculated as dose/AUC(0, 24 h). Analysis of the pharmacokinetic data from the single for the combined high and low clearance groups AB dose part of the and CD, respectively. Pharmacokinetic 11 by ANOVA. haemodynamic data from Drug dosage multiple dose part (Table 3) were analyzed by distri bution-free repeated measures analysis [9] . All other comparisons were assessed by Wilcoxon's rank sum test and Wilcoxon's signed Correlations were In the single dose part of the study patients of groups A assessed by determining the correlation coefficient and B received 1.0 mg cilazapril orally, whereas those according to Spearman or where appropriate according of groups C and D received 0.5 mg. Chronic cilazapril to Pearson. A P value of 0.05 was considered as the doses were 2.5, 2.5, 1.0 and 0.5 mg once daily in level of statistical significance. Unless otherwise indi groups A, B, C and D, respectively. If necessary, the cated, values are given as means ± s.d. dose was increased once at week 2 to 5.0 mg (groups A, B), 2.5 mg (group C) or 1.0 mg once daily (group D). Patient compliance was assessed by capsule counting and measurements of plasma ACE activity and cilazapri-Results lat concentrations.
Single dose

Other assessments
Patient characteristics are given in Table 1 . Phar macokinetic data are given in Figure 1 and Table 2 . In During the single dose part of the study regular contrast to groups A and B, cilazaprilat concentrations measurements of plasma concentrations of cilazaprilat declined slower in groups C and D. Accordingly, AUCs 
Chronic treatment
Cilazaprilat plasma concentrations, ACE inhibition, PRA levels Throughout the study cilazaprilat concentrations at 24 h were considerably lower in patients from groups A and B compared with patients from groups G and D (Table 3) . Increasing the dose resulted in slightly higher cilazaprilat concentrations only in groups CD. After week 4 cilazaprilat concentrations measured at 24 h remained stable. Together with the lower cilazapri lat concentrations ACE inhibition at 24 h was essentially lower in patients of the high clearance groups. ACE inhibition at 3 h after drug administration at week 2 and 4 was almost complete in all patients. In patients treated with the same ('S') and those treated with an increased ('1') dose, comparable levels of ACE inhibition were seen at week 11 at 24 h: 62 + 9 and 57+12% in the groups AB-S and AB-I (NS), and 85 + 10 and 90+4% in the groups CD-S and CD-I (NS), respect ively. PRA plasma concentrations at baseline were _1 in group AB i u 0.76 + 0.79 and 0.71 + 0.73 nmol 1' and CD (NS), respectively. In patients treated with the same ('S') or an increased ('1') dose PRA concentrations were not significantly different.
Time post d ose (h)
Blood pressure and heart rate Changes of mean arterial blood pressure are given in Table 3 . In patients getting the same dose, blood pressure reduction at 24 h remained essentially the same throughout the study. Increasing the dose at week 2 had no additional effect on blood pressure reduction at 24 h in the high clearance group (AB-I). In contrast, a slight decline of blood pressure after dose increase was observed in the patients of the low clearance group (CD-I). Heart rate did not essentially change in any group. No significant corre lation was found between BP decrease on the one hand and baseline MAP, cilazaprilat concentrations, ACE inhibition or urinary sodium excretion on the other.
Plasma cilazaprilat concentrations after a single dose of 1.0 and 0.5 mg cilazapril (CLcr>40 and <40 ml min"1, respectively). Cilazaprilat plasma concentrations of patients with an CLcr of less than 40 ml min-1 are normalized to a dose of 1 mg. Means + s.e. mean are given.
-----------CL". 5-20 ml min"1, n = Other assessments, adverse events In the low clearance groups CD serum creatinine and potassium concen trations had risen slightly from 364 + 102 at baseline to 410+138 |j.mol 1 (P mm n -5: CL CLcr > 100 ml min 21-40 ml <0.05) at week 11 and from 4.6 + 0.4 to 5.0+0.4mmol I-1 (P<0.05), respectively. Body weight essentially did not change. Proteinuria decreased from 3.5+ 2.2 at baseline to 2.0+1.2 gram day" 1 at week 11 (P<0.01) in the 10 patients with a proteinuria of more than 1 g day-1. No additional were larger in the low creatinine clearance groups. reduction in proteinuria was seen after increasing the Average time to peak concentration (fmax) was longer in dose at week 2. Compliance assessed by the percentage patients with renal insufficiency. Correlations were found of capsules used as expected for the number of treatment between CLcr and CL0 (r= +0.7594, P<0.001), between days was 98 (93-101), 100 (94-102), 100 (99-105) and
CLcr and t were possible since the provided drug bottles had seven inhibition were seen later in groups C and D (Figure 2) . capsules in excess of the expected number of treatment The correlation coefficient r between the degrees of ACE days). Two patients had short lasting dizziness during Unless otherwise indicated results are given as means ±s.d.; ** P < 0.01. Abbreviations: ANOVA: analysis of variance, AUC(0, 24 h): area under the curve, Cmax: peak concentration, tmax: time to peak concentration given as medians (ranges), CL0: apparent total body clearance. AUC(0, 24 h) and Cmax are normalized to a dose of one mg. Table 3 Cilazaprilat plasma concentrations (ng ml -1), baseline supine mean arterial blood pressures (MAP) and their percent changes during chronic treatment at 3 and 24 h after cilazapril intake in patients getting the same dose at week 2 ('S') and in patients in which dosage was increased at week 2 ('1') * P < 0.05 for ÀB-S vs AB-I and CD-S vs CD-I; results are given as means ± s.d the single dose part. In two patients dry cough was to higher plasma concentrations of probably related to the treatment with cilazapril.
relatively less binding to ACE and elimination. Longer times to peak after lower dosages of cilazapril have also been reported in normal volun teers [2] , In addition, the slower excretion of cilazaprilat in the low clearance groups may have contributed to the longer times to peak. Theoretically, slower intestinal In our patients with normal as well as in those with absorption of cilazapril in the low clearance groups may impaired renal function the pharmacokinetic data of the also explain this difference, but studies with other ACE Discussion single dose part were comparable with the results inhibitors are not in favour of such obtained by others [1, 3, 4] . A strong relationship
We can not compare our results between creatinine clearance on the one hand and AUC Pillastre et a l who found a higher Cmax in patients with hanism [10] . the study of ind clearance of cilazaprilat on the other hand was [3 ] observed. Time to peak was longer in patients with patients with a low creatinine clearance. Concentrations more severely impaired renal function. The lower dose of cilazaprilat at 96 h were low and the decline of the concentration was not given in the low clearance groups was reason for logarithm of the normalization to 1 mg. This may have biased the results linear and showed a wide interindividual variation as regarding time to peak, since the higher dose used in reported by others [2, 8] response and may be related to the normal course of chronic renal failure in these patients. However, since no control groups were included, this remains difficult to assess.
In conclusion, chronic treatment with cilazapril was safe in patients with an CLcr of 8-20 ml min-1 and 21-40 ml min-1 and a maximal once daily dosage of 1.0 and 2.5 mg, respectively. No cilazaprilat accumu lation was seen. Even at 24 h after drug administration cilazaprilat concentrations and degree of ACE inhibition in these low clearance groups were high and blood pressure response was adequate in most of the patients. In contrast, in most patients with an CLcr of more the 40 ml min ~1 no adequate blood pressure response was achieved at once daily dosing. References from time zero to infinity was inaccurate and therefore only results of AUC(0, 24 h) are presented here.
During chronic treatment cilazaprilat concentrations measured at 24 h were considerably lower in the high clearance than in the low clearance groups, in accordance with previously reported data [4, 5, 11] . Only in patients with a low creatinine clearance did the increase in drug dosage cause an increase in cilazaprilat concen trations at 24 h. However, no accumulation was seen in these groups. The duration of ACE inhibition was considerably longer in patients with more severe renal insufficiency. The degree of ACE inhibition was closely related to cilazaprilat concentrations, thereby confirming previous studies [4, 12] .
As expected from concentrations and degree of ACE inhibition a clear antihypertensive effect in all groups of patients was seen at 3 h after drug administration. In agreement with others [13] [14] [15] , the blood pressure reduction at 24 h remained small also after a dose increase in 12 out of 17 patients of the high clearance groups. In contrast, blood pressure at 24 h was slightly lower after increasing the dose in eight out of 12 patients with a low renal clearance. However, the extent of blood pressure decrease should be interpreted with caution since a placebo control is lacking.
In patients with a proteinuria of more than 1 g day-1 cilazapril clearly decreased urinary protein excretion by approximately 40%. Comparable antiproteinuric effects have been reported in the literature [5, 17] . Serum creatinine rose steadily only during the treatment in the low clearance groups. This increase was not influenced by the cilazapril dose or degree of the antihypertensive
